Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/TP.0000000000004829 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibody-suppressing CD8 + T-cell Therapy for Antibody-mediated Rejection: Clinical Considerations.
Transplantation
March 2024
Department of Surgery, Duke Transplant Center, Duke University School of Medicine, Durham, NC.
mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.
Transplantation
September 2016
1 Department of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH. 2 Center for Biostatistics, The Ohio State University, Columbus, OH.
Background: De novo alloantibodies (donor-specific antibody) contribute to antibody-mediated rejection and poor long-term graft survival. Because the development of donor-specific antibody is associated with early graft loss of cell transplants and reduced long-term survival of solid organ transplants, we hypothesized that conventional immunosuppressives, calcineurin inhibitors (CNi), and mammalian target of rapamycin inhibitors (mTORi), may not be as effective for suppression of humoral alloimmunity as for cell-mediated immunity.
Methods: Wild-type or CD8-depleted mice were transplanted with allogeneic hepatocytes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!